INVESTIGADORES
MARTIN Valentina
artículos
Título:
Toxoplasma gondii protease inhibitor-1 (TgPI-1) is a novel vaccine candidate against toxoplasmosis
Autor/es:
FERNANDEZ CUPPARI ANAHI; SANCHEZ VANESA; LEDESMA BIBIANA; FRANK FERNANDA M; GOLDMAN ALEJANDRA; ANGEL SERGIO O; MARTÍN VALENTINA
Revista:
VACCINE
Editorial:
Elsevier
Referencias:
Año: 2008 vol. 26 p. 5040 - 5045
ISSN:
0264-410X
Resumen:
The Toxoplasma gondii serin protease inhibitor-1 (TgPI-1) is a dense granule antigen that showed to specifically
inhibit trypsin, chymotrypsin and neutrophil elastase, suggesting a possible modulatory role during
the parasite invasion process and on the development of the innate immune response. To study the
immune-protective value of TgPI-1, C3H/HeN micewere immunized with a recombinant form of the antigen
rTgPI-1 combined with alum. All immunized mice produced specific anti-rTgPI-1 immunoglobulins,
with high IgG antibody titers and a mixed IgG1/IgG2a response, with predominance of IgG1 production. The
cellular immune response was associated with the production of IFN- and IL-10 cytokines. Vaccinated
mice displayed significant protection against an oral challenge either after a lethal infection with Me49
cysts (90% survival vs. 50%) and also after a non-lethal infection (58% reduction in brain parasite load)
compared to the non-vaccinated control group. In conclusion, rTgPI-1 elicits a strong specific immune
response providing partial protection against both T. gondii acute and chronic infection, so it would be a
good candidate in a vaccine against toxoplasmosis, which could be combined with other relevant parasite
antigens.Toxoplasma gondii serin protease inhibitor-1 (TgPI-1) is a dense granule antigen that showed to specifically
inhibit trypsin, chymotrypsin and neutrophil elastase, suggesting a possible modulatory role during
the parasite invasion process and on the development of the innate immune response. To study the
immune-protective value of TgPI-1, C3H/HeN micewere immunized with a recombinant form of the antigen
rTgPI-1 combined with alum. All immunized mice produced specific anti-rTgPI-1 immunoglobulins,
with high IgG antibody titers and a mixed IgG1/IgG2a response, with predominance of IgG1 production. The
cellular immune response was associated with the production of IFN- and IL-10 cytokines. Vaccinated
mice displayed significant protection against an oral challenge either after a lethal infection with Me49
cysts (90% survival vs. 50%) and also after a non-lethal infection (58% reduction in brain parasite load)
compared to the non-vaccinated control group. In conclusion, rTgPI-1 elicits a strong specific immune
response providing partial protection against both T. gondii acute and chronic infection, so it would be a
good candidate in a vaccine against toxoplasmosis, which could be combined with other relevant parasite
antigens.1/IgG2a response, with predominance of IgG1 production. The
cellular immune response was associated with the production of IFN- and IL-10 cytokines. Vaccinated
mice displayed significant protection against an oral challenge either after a lethal infection with Me49
cysts (90% survival vs. 50%) and also after a non-lethal infection (58% reduction in brain parasite load)
compared to the non-vaccinated control group. In conclusion, rTgPI-1 elicits a strong specific immune
response providing partial protection against both T. gondii acute and chronic infection, so it would be a
good candidate in a vaccine against toxoplasmosis, which could be combined with other relevant parasite
antigens. and IL-10 cytokines. Vaccinated
mice displayed significant protection against an oral challenge either after a lethal infection with Me49
cysts (90% survival vs. 50%) and also after a non-lethal infection (58% reduction in brain parasite load)
compared to the non-vaccinated control group. In conclusion, rTgPI-1 elicits a strong specific immune
response providing partial protection against both T. gondii acute and chronic infection, so it would be a
good candidate in a vaccine against toxoplasmosis, which could be combined with other relevant parasite
antigens.T. gondii acute and chronic infection, so it would be a
good candidate in a vaccine against toxoplasmosis, which could be combined with other relevant parasite
antigens.